Regulatory decisions, trial results, and industry developments as they land.
10 published pages
The FDA has cracked down on compounded GLP-1 agonists following shortage resolutions, while Congress has introduced the SAFE Drugs Act proposing…
5 sources
The FDA's reclassification of 12 peptides from Category 2 restrictions in April 2026 has reopened the door for compounding pharmacies. With the…
5 sources
GLP-1 agonist shortages have resolved, but affordability barriers persist as FDA enforcement ends compounded alternatives. The first generic…
5 sources
The longevity biotech sector has attracted over $13 billion in venture funding, with companies like Retro Biosciences and NewLimit raising massive…
5 sources
The FDA's approval of oral Wegovy in December 2025 and Eli Lilly's Foundayo (orforglipron) in 2026 mark a turning point for peptide drug delivery…
6 sources
Peptide-drug conjugates are advancing rapidly with six candidates in Phase III trials and 96 in development. Offering deeper tissue penetration and…
5 sources
The global peptide therapeutics market reached $131.95 billion in 2025 and is projected to hit $334.95 billion by 2034. Fueled by GLP-1 blockbusters…
5 sources
Mount Sinai's PGV001 personalized peptide cancer vaccine showed durable responses across five tumor types in Phase 1, with three of six surviving…
5 sources
Tirzepatide continues to expand beyond diabetes, with FDA approval for obstructive sleep apnea, landmark cardiovascular outcomes data from the…
5 sources